SHASUN PHARMA SOLUTIONS INC. BALANCE SHEET AS AT MARCH 31, 2019

	DALANCE SHILLI AS AT		2013	
			Amount in USD 31-Mar-19	Amount in USD 31-Mar-18
Α	ASSETS	_	5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	TOTAL ASSETS	=	-	-
В	EQUITY AND LIABILITIES			
ı	Equity			
	(a) Equity share capital	1	547,361	547,361
	(b) Other equity	2	(552,198)	(553,463)
	Total Equity	•	(4,838)	(6,102)
II	Liabilities			
1	Current liabilities			
	(a) Financial liabilities			
	(i) Trade payables	3	-	2,750
	(ii) Other financial liabilities	4	4,838	3,102
	(b) Current income tax liabilities	5	-	250
	Total current liabilities	•	4,838	6,102
	TOTAL EQUITY AND LIABILITIES	- -	-	

SHASUN PHARMA SOLUTIONS INC. STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019

Amount in USD Amount in USD Note **Particulars** 31-Mar-19 31-Mar-18 No. **1** Revenue from operations 2 Other Income 3 Total Revenue (1+2) -4 Expenses (a) Other expenses 6 (1,265)2,000 **Total expenses** (1,265)2,000 5 Profit / (Loss) before exceptional items and taxes (3-4) 1,265 (2,000) **6** Exceptional Item 7 Profit / (Loss) before taxes (5+6) (2,000) 1,265 8 Tax Expense: 1,102 (1) Current tax (2) Deferred tax Total tax expenses 1,102

1,265

(3,102)

VII Profit / (Loss) for the year after tax

SHASUN PHARMA SOLUTIONS INC. STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2019

(A) Equity share capital

Particulars	Amount in USD
Balance as at March 31, 2017	547,361
Changes in equity share capital during the year	-
Balance as at March 31,2018	547,361
Changes in equity share capital during the year	-
Balance as at March 31, 2019	547,361

(B) Other equity Amount in USD

Other equity				Amount in OSD
	Snare	Reserves and	Items of other	
	application	surplus	comprehensive income	
Particulars	money		Re -measurement of the	Total
	pending		defined benefit liabilities /	
	allotment	Retained earnings	(assets)	
Balance as at March 31,2017	-	(550,361)	-	(550,360.87)
Profit/loss for the vear		(3,102)		(3.102)
Other comprehensive income for the year (net of tax)				-
Balance as at March 31,2018	-	(553,463)	-	(553,463)
Application money received during the year	-			-
Profit/loss for the year	-	1,265	-	1,265
Other comprehensive income for the year (net of tax)	-		-	-
Balance as at March 31, 2019	-	(552,198)	-	(552,198)

SHASUN PHARMA SOLUTIONS INC. Notes forming part of financial statement

Note

No.

1	Share capital		Amount in USD
	Particulars	31-Mar-19	31-Mar-18
	Issued, subscribed and fully paid-up		
	Equity share capital	547,361	547,361
	Total	547,361	547,361

Particulars	31-Mar-19	31-Mar-18
Surplus in statement of profit and loss		
Opening balance	(553,463)	(550,361
Add: Profit / (Loss) for the year	1,265	(3,102
Closing balance	(552,198)	(553,463
•	, , , , , , ,	,,
Total	(552.198)	(553.46

3	Trade payables		Amount in USD
	Particulars	31-Mar-19	31-Mar-18
	Trade payable	-	2,750
	Total		2,750

Other Current financia	Particulars	31-Mar-19	Amount in USE 31-Mar-18
	rai ticulai s	31-IVIAI-13	
Payable to group entit	es	4,838	3,102
Total		4,838	3,102
•		•	
Current Income tax lia	blility		Amount in USE
	Darticulars	21 Mar 10	21 Mar 19

Particulars	31-Mar-19	31-Mar-18
Provision for income tax (net of advance tax)	-	250
Income Tax Liability (Net of Advance Tax)		
Total	-	250

SHASUN PHARMA SOLUTIONS INC. Notes forming part of financial statement

Note

No.

6 Other expenses Amount in USD

Particulars	31-Mar-19	31-Mar-18
Rates & Taxes	1,486	-
Professional fees	-	2,000
Payment to Auditors - For Statutory Audit	(2,750)	-
Total	(1,265)	2,000